About MannKind

MannKind Corporation (Nasdaq and TASE: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients.

AFREZZA® (pronounced uh-FREZZ-uh), approved in 2014 by the U.S. Food and Drug Administration, is a rapid-acting inhaled insulin therapy indicated to improve glycemic control in adults with diabetes. Taken at the start of a meal using a specially designed inhaler, Afrezza dissolves rapidly upon inhalation to the deep lung and delivers insulin quickly to the bloodstream. Peak insulin levels are achieved within 12 to 15 minutes of use and help to control post-meal blood sugar spikes that affect HbA1C levels.  More >

 

                    follow me on twitter       find us on facebook

 
For more information about AFREZZA, please visit www.Afrezza.com.

 Spotlight

Matthew J. Pfeffer, CEO/CFO and Raymond W. Urbanski, CMO held an investor conference call on February 3 to update on company developments.  To view the slide deck Click Here. To view related FAQs Click Here.

 

To view the FAQ: Technosphere® licensing agreement announced by MannKind™, January 21, 2016. Click Here

News & Events

   
Apr 19, 2016 MannKind Expands Commercial Capabilities With Two New Hires More >
Apr 19, 2016 Analyst Call Rescheduled to April 26, 2016 More >
Apr 11, 2016 MannKind to Discuss U.S. Commercialization Update for Afrezza® More >